Αρχειοθήκη ιστολογίου

Αναζήτηση αυτού του ιστολογίου

Παρασκευή 17 Νοεμβρίου 2017

Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathologic analysis and detection of the gene fusion by RNA-sequencing and FISH

Abstract

Aims

MITF, TFE3, TFEB and TFEC belong to the same microphthalmia-associated transcription factor family (MiT). Two transcription factors in this family have been identified in two unusual types of renal cell carcinoma (RCC): Xp11 translocation RCC harboring TFE3 gene fusions and t(6;11) RCC harboring a MALAT1-TFEB gene fusion. The 2016 World Health Organization classification of renal neoplasia grouped these two neoplasms together under the category of MiT family translocation RCC. RCCs associated with the other two MiT family members, MITF and TFEC, have rarely been reported. Herein, we identify a case of MITF translocation RCC with the novel PRCC-MITF gene fusion by RNA-sequencing.

Methods and Results

Histological examination of the present tumor showed typical features of MiT family translocation RCCs, overlapping with Xp11 translocation RCC and t(6;11) RCC. However, this tumor showed negative results in TFE3 and TFEB immunochemistry and split fluorescence in situ hybridization (FISH) assays. The other MiT family members, MITF and TFEC, were immunochemically tested further and showed negative results as well. RNA-sequencing and reverse transcription polymerase chain reaction confirmed the presence of a PRCC-MITF gene fusion: a fusion of PRCC exon 5 to MITF exon 4. We then developed FISH assays covering MITF break-apart probes and PRCC-MITF fusion probes to detect the MITF gene rearrangement.

Conclusions

This study both proves the recurring existence of MITF translocation RCC and expands the genotype spectrum of MiT family translocation RCCs.

This article is protected by copyright. All rights reserved.



http://ift.tt/2hvM0NM

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.